CN Patent

CN111989101A — 具有受控溶出的水性悬浮液型药物制剂

Assigned to Sumitomo Pharma Co Ltd · Expires 2020-11-24 · 5y expired

What this patent protects

本发明提供了一种水性悬浮液型药物制剂，其即使当口服施用时也会抑制过早的溶出和吸收，具有相对低的由血液中浓度的暂时增加造成的意外副作用的开始的风险，且含有(1)‑(4)。(1)(3aR,4S,7R,7aS)‑2‑{(1R,2R)‑2‑[4‑(1,2‑苯并异噻唑‑3‑基)哌嗪‑1‑基甲基]环己基甲基}六氢‑4,7‑桥亚甲基‑2H‑异吲哚‑1,3‑二酮，其药学上可接受的酸加成盐，或这些的混合物；(2)黄原胶；(3)分散剂；和(4)水。

USPTO Abstract

本发明提供了一种水性悬浮液型药物制剂，其即使当口服施用时也会抑制过早的溶出和吸收，具有相对低的由血液中浓度的暂时增加造成的意外副作用的开始的风险，且含有(1)‑(4)。(1)(3aR,4S,7R,7aS)‑2‑{(1R,2R)‑2‑[4‑(1,2‑苯并异噻唑‑3‑基)哌嗪‑1‑基甲基]环己基甲基}六氢‑4,7‑桥亚甲基‑2H‑异吲哚‑1,3‑二酮，其药学上可接受的酸加成盐，或这些的混合物；(2)黄原胶；(3)分散剂；和(4)水。

Drugs covered by this patent

Patent Metadata

Patent number: CN111989101A
Jurisdiction: CN
Classification: —
Expires: 2020-11-24
Drug substance claim: No
Drug product claim: No
Assignee: Sumitomo Pharma Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.